Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale, .
Victory Square Technologies Inc.January 11, 2021 GMT
Victory Square Health received Brazilian ANVISA approval for Safetest 15 Minute Covid-19 Rapid Test for distribution, sale, and usage in Brazil
The Safetest 15 Minute Covid-19 Rapid Test has a 96.6% Sensitivity, and can confirm whether one is currently infected with the Covid-19 virus or whether one was infected prior and unaware of the infection
On November 17th, 2020, the Company announced a strategic partnership with Molkom Pharmaceuticals to sell and distribute its Safetest Covid-19 Rapid and other Tests in Brazil and for export to Mercosur Countries
Victory Square Technologies Portfolio Company Receives Brazilian ANVISA Approval for Sale, Distribution & Use of Safetest 15 Minute Covid-19 Rapid Test for Brazil Victory Square Technologies Inc. Vancouver, British Columbia, CANADA
Victory Square Health received Brazilian ANVISA approval for Safetest 15 Minute Covid-19 Rapid Test for distribution, sale, and usage in Brazil
The Safetest 15 Minute Covid-19 Rapid Test has a 96.6% Sensitivity, and can confirm whether one is currently infected with the Covid-19 virus or whether one was infected prior and unaware of the infection
On November 17th, 2020, the Company announced a strategic partnership with Molkom Pharmaceuticals to sell and distribute its Safetest Covid-19 Rapid and other Tests in Brazil and for export to Mercosur Countries
Victory Square Provides Corporate Update on Record Year
Net income for the nine-month period ending September 30th, 2020 was $13,617,124 and earnings per share of $0.18 Completed an oversubscribed $6.1 Million private placement Significant growth by Victory Square companies in key sectors: Digital Health, eSports, Gaming, Crypto, ARVR, Cybersecurity, Cloud Computing and Plant-based Sciences Victory Square spin-off, FansUnite Entertainment Inc., reached $150 Million CAD … Net income for the nine-month period ending September 30th, 2020 was $13,617,124 and earnings per share of $0.18 Completed an oversubscribed $6.1 Million private placement Significant growth by Victory Square companies in key sectors: Digital Health, eSports, Gaming, Crypto, AR/VR, Cybersecurity, Cloud Computing and Plant-based Sciences
Victory Square Technologies Receives Approval for Sale & Distribution of VS SARS CoV-2 Antigen 15 Minute Nasal Rapid Test for Entire European Union - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Share:
Victory Square Technologies received the CE designation from the European Union (EU) competent authority of Belgium for VS SARS CoV-2 Antigen Rapid 15 Minute test on December 18th, 2020.
The Company s VS SARS CoV-2 Antigen 15 Minute Nasal Rapid Test has a 92 % Sensitivity, 99.2% Specificity, and can confirm whether one is currently infected with the virus causing Covid-19 and is unaware of the infection
This Covid-19 Rapid Antigen Test approval further enables Victory Square Technologies to distribute all three testing products (Elisa, Antibody & Antigen) throughout the 27 EU & EEA countries with a combined population of 446,824,564
This EU approval for the Company s VS SARS CoV-2 Antigen 15 Minute Nasal Rapid Test is in addition to the Company s Safetest Covid-19 Antibody 15 Minute Rapid Test previously approved and issued by the EU/EEA on October 16, 2020